Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 14/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481275 | 1.00 | TAAR1 (0.63) | TAAR1MAPTNPSR1MAPK1HTR2A | |
| SCHEMBL16053760 | 0.84 | TAAR1 (0.62) | TAAR1MAPTNPSR1MAPK1HTR2A | |
| SCHEMBL608459 | 0.83 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL31142838 | 0.83 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL27625511 | 0.81 | TAAR1 (0.39) | TAAR1 | |
| SCHEMBL22308209 | 0.81 | GABRA1 (0.43) | TAAR1 | |
| Hydrochloric Acid SCHEMBL1364635 | 0.81 | TAAR1 (0.43) | TAAR1 | |
| SCHEMBL1244819 | 0.79 | TAAR1 (0.38) | TAAR1 | |
| SCHEMBL726804 | 0.78 | TAAR1 (0.68) | TAAR1MAPTNPSR1MAPK1HTR2A | |
| SCHEMBL29423333 | 0.78 | TAAR1 (1.00) | TAAR1HTR2AHTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| WO-2023174383-A1 | DIHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-09-21 | — | — | WO | disclosed |
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| US-10961241-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-04-04 | — | — | US | disclosed |
| WO-2017182493-A1 | INDAZOLE DERIVATIVES FOR USE IN DOWN-REGULATION OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017182495-A1 | INDAZOLE DERIVATIVES THAT DOWN-REGULATE THE ESTROGEN RECEPTOR AND POSSESS ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| EP-2847174-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013151923-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-1112998-B1 | AMINE DERIVATIVES | POLA CHEM IND INC (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | TAAR1 897/4885MAPT 252/4885NPSR1 907/4885 |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TAAR1 3455/4885MAPT 1908/4885NPSR1 2252/4885 |
| US-10961241-B2 | Chemical compounds | MKI67, CCNI, MCL1 | TAAR1 3455/4885MAPT 1908/4885NPSR1 2252/4885 |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TAAR1 3455/4885MAPT 1908/4885NPSR1 2252/4885 |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TAAR1 3455/4885MAPT 1908/4885NPSR1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.